Aurobindo Pharma reported consolidated revenue from operation at `40490mn up 11% on YoY basis and a decline of 6.62 % on QoQ basis. The sequential decline in revenue was mainly because of product recall and stoppage of a bag line in the injectable business. EBITDA was reported at `7881mn, up by 9% YoY and decline of 23% on QoQ basis. EBITDA...